$1.55

0.038 (2.48%)

1 Oct 2015
Buy
below
Hold
up to
Sell
above
Buy Hold Sell Meter
Locked Recommendation

Analysis

Overview

Current recommendation Preview
Business risk 0
Share price risk 0

General Information

Mayne Pharma Group Limited
MYX
http://www.maynepharma.com
Pharmaceuticals
1,223
810

Current Price Data+

Current Price $1.548
Open $1.520
High $1.555
Low $1.515
Last Close $1.510
Volume 2238114
Price Movement $0.04 ( 2.48% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Stock Price

Current Broker Consensus Recommendation

Buy
23 May 2016
3

Company Overview

Business Description

Mayne Pharma Group Limited (MYX) is a pharmaceutical company that develops and manufactures branded and generic products, which it distributes directly or through distribution partners in Australia, USA, Europe and Asia. MYX also provides contract development and manufacturing services.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2017 F 47.8 7.1 19.4% 20.8 0.0 0.0% 100.0%
2016 F 40.0 5.9 430.5% 24.8 0.0 0.0% 100.0%
2015 A 7.5 1.1 -73.1% 75.8 0.0 0.0% 100.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2015 A 2016 F 2017 F 2015 A 2016 F 2017 F 2015 A 2016 F 2017 F
Mayne Pharma Group (MYX) $1,191M -0.3897 2.1675 0.1008 76.9634 24.2975 22.0721 0.00% 0.00% 0.00%
Starpharma (SPL) $257M 0.0000 0.0000 0.0000 0.0000 0.0000 20.5882 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.54 26.70 3.82 0.31
Market 0.99 16.40 1.30 1.69
Sector 0.50 15.30 3.16 0.68

Directors

Name Position Start Date
Mr Scott Anthony Richards Chief Executive Officer, Managing Director 13 Feb 2012
Mr Roger Campbell Corbett Non-Executive Chairman 17 Nov 2010
Mr Bruce L Mathieson Non-Executive Director 16 Feb 2007
Mr Ian Frank Scholes Non-Executive Director 17 Oct 2007
Hon Ron Best Non-Executive Director 26 Jul 2006
Mr William Phillip Hodges Non-Executive Director 15 Nov 2012
Professor Bruce G Robinson Non-Executive Director 26 Aug 2014

Management

Name Position
Mark Cansdale Chief Financial Officer,Company Secretary
Ilana Stancovski Chief Scientific Officer
Stefan Cross President of Mayne Pharma USA

Substantial Shareholders

Holding Name
0 (7.30%) Westpac Banking Corporation
0 (7.30%) BT Investment Management Limited
0 (7.20%) B L Mathieson
0 (5.10%) Thorney International Pty Ltd

Calendar of Events

Date Event
24 February 2017 Report (Interim)
26 August 2016 Report (Prelim)
26 August 2016 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.